Abstract
This report presents the case of an 8-year-old male with biventricular hypertrophic obstructive cardiomyopathy who achieved a successful reduction of the pressure gradients by treatment with cibenzoline. Ultrasound echocardiography showed marked intraventricular septal hypertrophy and left midventricular and right ventricular outflow obstructions. A cardiac catheterization revealed left midventricular and right outflow obstructions associated with pressure gradients of 100 and 35 mmHg, respectively. An intravenous injection of 28 mg (1.4 mg/kg) cibenzoline immediately improved the biventricular pressure gradients. Therefore, oral cibenzoline treatment was initiated, the dose was increased to 150 mg/day, and both pressure gradients remained low, without any complications at the time of discharge, 4 months later.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hamada M, Shigematsu Y, Ikeda S et al (1997) Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 96:1520–1524
Hamada M, Shigematsu Y, Hara Y et al (2001) Antiarrythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ J 65:531–538
Hiasa G, Hamada M, Shigematsu Y et al (2002) Attenuation of biventricular pressure gradients by cibenzoline in an 18-year-old patient with hypertrophic obstructive cardiomyopathy. Circ J 66:1173–1175
Holck M, Osterrieder W (1986) Inhibition of the myocardial Ca2+ inward current by by the class I antiarrhythmic agent, cibenzoline. Br J Pharmacol 87:705–711
Konishi C, Shiraishi J, Muraguchi N et al (2004) Benefical effect of cibenzoline on left ventricular pressure gradient with sigmoid septum. Circ J 68:968–971
Maron BJ, Tajik AJ, Ruttenberg HD (1982) Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circuration 65:7–17
Maron BJ, Casey SA, Poliac LC et al (1999) Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281:650–655
Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295–303
Masatoshi S, Hiroya K, Yoshiyuki Y et al (2003) Echocardiographic assessment of right ventricular obstruction in hypertrophic cardiomyopathy. Circ J 67:855–860
Matsuoka S, Nawada T, Hisatome I et al (1991) Comparison of Ca2+ channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart. Gen Pharmacol 22:87–91
Morrow AG, Fisher RD, Fogarty TJ (1969) Isolated hypertrophic obstruction to right ventricular outflow: clinical, hemodynamic, and angiographic findings before and after operative treatment. Am Heart J 77:814–817
Nugent AW, Daubeney PE, Chondros P (2005) Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 112:1332–1338
Pollick C (1982) Muscular subaortic stenosis. Hemodynamic and clinical improvement after disopyramide. N Engl J Med 307:997–999
Takahashi K, Kogaki S, Kurotobi S et al (2005) A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. Eur J Pediatr 164:497–500
Theodoro DA, Danielson GK, Feldt RH et al (1996) Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. J Thorac Cardiovasc Surg 112:1589–1599
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishikawa, T., Iwashima, S. & Ohzeki, T. Effect of Cibenzoline on Biventricular Pressure Gradients in a Pediatric Patient with Hypertrophic Obstructive Cardiomyopathy. Pediatr Cardiol 31, 707–710 (2010). https://doi.org/10.1007/s00246-010-9651-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-010-9651-7